TR-987(TR-987) - 药物靶点：TLR2_在研适应症：慢性静脉功能不全，静脉曲张溃疡，创伤和损伤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Glucoprime

+ [3]

靶点

TLR2

作用方式

调节剂、刺激剂

作用机制

TLR2调节剂(Toll样受体2调节剂)、巨噬细胞刺激剂

治疗领域

心血管疾病皮肤和肌肉骨骼疾病其他疾病

在研适应症

慢性静脉功能不全静脉曲张溃疡创伤和损伤

非在研适应症-

原研机构

Kazia Therapeutics Ltd.

在研机构

TR Therapeutics, Inc.

Kazia Therapeutics Ltd.

非在研机构

Glycotex, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 TR-987 相关的临床试验

NCT06707090

/ Recruiting临床3期

A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)

The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.

开始日期2024-11-01

申办/合作机构

TR Therapeutics, Inc.

NCT06707103

/ Recruiting临床3期

A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)

The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.

开始日期2024-11-01

申办/合作机构

TR Therapeutics, Inc.

NCT03154619

/ Active, not recruiting临床2期

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial.

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

开始日期2016-11-01

申办/合作机构

SerenaGroup, Inc.

[+1]

100 项与 TR-987 相关的临床结果

登录后查看更多信息

100 项与 TR-987 相关的转化医学

登录后查看更多信息

100 项与 TR-987 相关的专利（医药）

登录后查看更多信息

1

项与 TR-987 相关的文献（医药）

2011-05-01·Wound Repair and Regeneration3区 · 医学

Particulate β‐glucan induces TNF‐α production in wound macrophages via a redox‐sensitive NF‐κβ‐dependent pathway

3区 · 医学

Article

作者: Savita Khanna ; Eric Collard ; Sashwati Roy ; Chandan K. Sen ; Urmila Gnyawali ; Gayle M. Gordillo ; Ryan Dickerson

ABSTRACTGlucans are known to promote wound repair. Noncellulosic β‐glucans are recognized as potent immunological activators. β‐Glucans are generally safe and are known to attenuate the rate of postoperative infection. Glyc101 is a particulate β‐glucan isolated from Saccharomyces cerevisiae. In this study, the hypothesis that Glyc101 regulates wound macrophage function was tested. Glyc101 induced tumor necrosis factor (TNF) α transcription in macrophages isolated from murine wound site. Multiplex assay identified interleukin (IL)‐10 and TNFα as two cytokines that are induced by Glyc101 in human blood monocyte‐derived macrophages. Glyc101‐induced TNFα production was observed to be mediated via the TLR‐2 and dectin‐1 receptors, receptor tyrosine kinases and NFκB activation. In murine wound macrophages, Glyc101 potentiated phorbol 12‐myristate 13‐acetate‐induced respiratory burst. In vivo, implantation of Glyc101‐enriched polyvinyl alcohol‐sponges at the wound‐site induced TNFα expression in macrophages. Consistently, Glyc101 induced TNFα expression in wound‐site macrophages isolated from two patients with chronic wounds. These observations establish the translational significance of the net findings of this study. Activation of wound macrophages by Glyc101 represents one of the potential mechanisms by which this β‐glucan may benefit chronic wounds where inefficient inflammatory response is one of the underlying causes of impaired healing.

100 项与 TR-987 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性静脉功能不全	临床3期	美国	TR Therapeutics, Inc.	2024-11-01
慢性静脉功能不全	临床3期	澳大利亚	TR Therapeutics, Inc.	2024-11-01
静脉曲张溃疡	临床3期	美国	TR Therapeutics, Inc.	2024-11-01
静脉曲张溃疡	临床3期	澳大利亚	TR Therapeutics, Inc.	2024-11-01
创伤和损伤	临床3期	美国	TR Therapeutics, Inc.	2024-11-01
创伤和损伤	临床3期	澳大利亚	TR Therapeutics, Inc.	2024-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	临床2期	慢性静脉功能不全	82	TR987® 0.1% gel	鬱壓憲鬱淵顧艱窪鑰鑰(淵襯壓獵構繭鬱淵鬱築) = 繭網鹹網蓋製範壓製遞築鏇夢鏇鏇窪淵鑰鬱糧 (蓋衊構願膚衊觸窪齋淵 ) 更多	积极	2023-07-03
				Placebo gel	鬱壓憲鬱淵顧艱窪鑰鑰(淵襯壓獵構繭鬱淵鬱築) = 鹽願鹹獵製襯獵選顧艱築鏇夢鏇鏇窪淵鑰鬱糧 (蓋衊構願膚衊觸窪齋淵 ) 更多
NCT00656474 (CTgov)	临床1/2期	创伤和损伤	12	GLYC-101 (GLYC-101 Active Retro-auricular Site (1 Per Participant))	獵顧蓋憲築壓廠遞醖衊(獵艱觸繭鏇膚簾夢鹹糧) = 選壓觸選鏇齋廠淵糧鑰廠糧構糧製糧衊窪獵艱 (遞築顧構鏇醖願蓋鹽鬱, 構繭遞鹹艱淵淵鑰淵遞 ~ 觸鹽憲獵艱獵鹹膚鏇鹹) 更多	-	2011-07-25
				Placebo (Placebo Retro-auricular Site (1 Per Participant))	獵顧蓋憲築壓廠遞醖衊(獵艱觸繭鏇膚簾夢鹹糧) = 觸廠膚鑰壓艱襯積艱選廠糧構糧製糧衊窪獵艱 (遞築顧構鏇醖願蓋鹽鬱, 構淵鑰選蓋餘簾夢襯艱 ~ 膚構膚鏇鏇願衊醖窪觸) 更多